PL381862A1 - Zastosowanie związków pirydyniowych i sposób leczenia - Google Patents

Zastosowanie związków pirydyniowych i sposób leczenia

Info

Publication number
PL381862A1
PL381862A1 PL381862A PL38186207A PL381862A1 PL 381862 A1 PL381862 A1 PL 381862A1 PL 381862 A PL381862 A PL 381862A PL 38186207 A PL38186207 A PL 38186207A PL 381862 A1 PL381862 A1 PL 381862A1
Authority
PL
Poland
Prior art keywords
treatment
manner
application
pyridine compounds
pyridine
Prior art date
Application number
PL381862A
Other languages
English (en)
Inventor
Stefan Chłopicki
Andrzej Marcinek
Jerzy Gębicki
Jan Adamus
Original Assignee
Trigendo Spółka Z Ograniczoną Odpowiedzialnością
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trigendo Spółka Z Ograniczoną Odpowiedzialnością filed Critical Trigendo Spółka Z Ograniczoną Odpowiedzialnością
Priority to PL381862A priority Critical patent/PL381862A1/pl
Priority to ES08719457T priority patent/ES2388586T3/es
Priority to RU2009135821/15A priority patent/RU2477132C2/ru
Priority to PL08719457T priority patent/PL2124946T3/pl
Priority to DK08719457.7T priority patent/DK2124946T3/da
Priority to PT08719457T priority patent/PT2124946E/pt
Priority to CA2714601A priority patent/CA2714601A1/en
Priority to PCT/IB2008/050666 priority patent/WO2008104920A1/en
Priority to EP08719457A priority patent/EP2124946B1/en
Priority to US12/038,381 priority patent/US7893095B2/en
Publication of PL381862A1 publication Critical patent/PL381862A1/pl
Priority to US13/011,364 priority patent/US8377972B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PL381862A 2007-02-28 2007-02-28 Zastosowanie związków pirydyniowych i sposób leczenia PL381862A1 (pl)

Priority Applications (11)

Application Number Priority Date Filing Date Title
PL381862A PL381862A1 (pl) 2007-02-28 2007-02-28 Zastosowanie związków pirydyniowych i sposób leczenia
PT08719457T PT2124946E (pt) 2007-02-28 2008-02-25 Uso de derivados de n-metilpiridínio em hepatoprotecção
RU2009135821/15A RU2477132C2 (ru) 2007-02-28 2008-02-25 Применение четвертичных соединений пиридиния для вазопротекции и/или гепатопротекции
PL08719457T PL2124946T3 (pl) 2007-02-28 2008-02-25 Zastosowanie pochodnych N-metylopirydyniowych do hepatoprotekcji
DK08719457.7T DK2124946T3 (da) 2007-02-28 2008-02-25 Anvendelse af N-methylpyridiniumderivater til hepatobeskyttelse
ES08719457T ES2388586T3 (es) 2007-02-28 2008-02-25 Uso de derivados de N-metil-piridinio para hepatoprotección
CA2714601A CA2714601A1 (en) 2007-02-28 2008-02-25 The use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection
PCT/IB2008/050666 WO2008104920A1 (en) 2007-02-28 2008-02-25 The use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection
EP08719457A EP2124946B1 (en) 2007-02-28 2008-02-25 The use of n-methyl pyridinium derivatives for hepatoprotection
US12/038,381 US7893095B2 (en) 2007-02-28 2008-02-27 Use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection
US13/011,364 US8377972B2 (en) 2007-02-28 2011-01-21 Use of quaternary pyridinium compounds for vasoprotection and/or hepatoprotection

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL381862A PL381862A1 (pl) 2007-02-28 2007-02-28 Zastosowanie związków pirydyniowych i sposób leczenia

Publications (1)

Publication Number Publication Date
PL381862A1 true PL381862A1 (pl) 2008-09-01

Family

ID=39596548

Family Applications (2)

Application Number Title Priority Date Filing Date
PL381862A PL381862A1 (pl) 2007-02-28 2007-02-28 Zastosowanie związków pirydyniowych i sposób leczenia
PL08719457T PL2124946T3 (pl) 2007-02-28 2008-02-25 Zastosowanie pochodnych N-metylopirydyniowych do hepatoprotekcji

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL08719457T PL2124946T3 (pl) 2007-02-28 2008-02-25 Zastosowanie pochodnych N-metylopirydyniowych do hepatoprotekcji

Country Status (9)

Country Link
US (2) US7893095B2 (pl)
EP (1) EP2124946B1 (pl)
CA (1) CA2714601A1 (pl)
DK (1) DK2124946T3 (pl)
ES (1) ES2388586T3 (pl)
PL (2) PL381862A1 (pl)
PT (1) PT2124946E (pl)
RU (1) RU2477132C2 (pl)
WO (1) WO2008104920A1 (pl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL364348A1 (pl) 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
US8304439B1 (en) 2007-10-12 2012-11-06 Politechnika Lodzka Use of quaternary pyridinium salts as a therapeutic or preventing agent against ionizing radiation-induced damage
EP2211857B1 (en) * 2007-10-12 2012-09-12 Politechnika Lodzka Use of quaternary pyridinium salts for radioprotection
EP2186419A1 (en) * 2008-11-13 2010-05-19 Tchibo GmbH NMP-containing extract, a method of its production and uses thereof
CN102231982A (zh) * 2008-11-17 2011-11-02 慕尼黑理工大学 用于糖尿病治疗和预防的方法和组合物
WO2012107364A1 (en) * 2011-02-07 2012-08-16 Scipharm Sàrl Novel composition for the treatment of cystic fibrosis
KR101753244B1 (ko) * 2016-02-05 2017-07-11 (주)노터스생명과학 트리고넬린을 유효성분으로 포함하는 숙취 해소 및 간기능 개선용 조성물
MX2019000721A (es) * 2016-07-18 2019-06-10 Pharmena S A 1-metilnicotinamida para el tratamiento de enfermedades asociadas con la proteína c reactiva.
WO2024095178A1 (en) 2022-11-01 2024-05-10 Janssen Pharmaceutica Nv Thrombopoietin mimetic for use in the treatment of acute liver failure

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7189865B2 (en) * 2002-07-23 2007-03-13 Attenuon, Llc Thiomolybdate analogues and uses thereof
US7674486B2 (en) * 2003-05-14 2010-03-09 Indus Biotech Pvt. Ltd. Synergistic composition for the treatment of diabetes mellitus
PL364348A1 (pl) * 2004-01-12 2005-07-25 PHARMENA Sp.z o.o. Zastosowanie czwartorzędowych soli pirydyniowych jako środka naczynioprotekcyjnego
US20050267015A1 (en) * 2004-05-04 2005-12-01 Batarseh Kareem I Method of treatment and composition for inhibiting the production of toxic free radical and reactive oxygen species using metalloproteins found in bacteria
WO2006024545A1 (en) * 2004-09-03 2006-03-09 Stichting Voor De Technische Wetenschappen Fused bicyclic natural compounds and their use as inhibitors of parp and parp-mediated inflammatory processes
DE102005029468A1 (de) * 2005-06-24 2006-12-28 Plt Patent & Licence Trading Ltd. Verwendung von Inhibitoren der N-Methyltransferasen in der Therapie des Parkinson-Syndroms
AU2007223787A1 (en) * 2006-03-08 2007-09-13 Pharmena North America Inc. Combination therapy with non-selective COX inhibitors to prevent COX-related gastric injuries

Also Published As

Publication number Publication date
US20080221172A1 (en) 2008-09-11
RU2009135821A (ru) 2011-04-10
PL2124946T3 (pl) 2012-10-31
US8377972B2 (en) 2013-02-19
ES2388586T3 (es) 2012-10-16
PT2124946E (pt) 2012-08-24
DK2124946T3 (da) 2012-09-03
US20110118316A1 (en) 2011-05-19
RU2477132C2 (ru) 2013-03-10
EP2124946A1 (en) 2009-12-02
US7893095B2 (en) 2011-02-22
CA2714601A1 (en) 2008-09-04
EP2124946B1 (en) 2012-05-23
WO2008104920A1 (en) 2008-09-04

Similar Documents

Publication Publication Date Title
GB0719803D0 (en) Therapeutic compounds and their use
EP2118074A4 (en) COMPOUNDS FOR THE PREVENTION AND TREATMENT OF CARDIAC DISEASES
EP2097012A4 (en) DEVICES AND METHOD FOR TREATING HEART FAILURE
GB0719644D0 (en) Therapeutic compounds and their use
EP2361089A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF ALTERED FUNCTION OF -SYNUCLEINE
IL210810A0 (en) Compositions for the treatment of pain and/or inflamtion
IL205562A0 (en) Benzodiazepinone compounds useful in the treatment of skin conditions
GB0724251D0 (en) Therapeutic compounds and their use
GB0722680D0 (en) Therapeutic compounds and their use
PL381862A1 (pl) Zastosowanie związków pirydyniowych i sposób leczenia
IL205137A0 (en) 5-cyanothienopyridines for the treatment of tumours
HRP20130395T1 (en) Treatment of melanoma
IL202523A0 (en) Buspirone for the treatment of mausea and vomiting
EP2007790A4 (en) COMPOUNDS AND METHODS FOR THE TREATMENT OF PAIN
GB0723100D0 (en) Treatment of HFnEF
EP2231163A4 (en) COMPOUNDS AND THEIR THERAPEUTIC USE
EP2164494A4 (en) Methods of Treatment
HK1185345A1 (zh) 用於預防和治療心血管疾病的化合物
GB0714500D0 (en) composition and treatment
EP2077797A4 (en) IMPLANTABLE DEVICES AND METHODS OF FORMATION THEREOF
HK1209754A1 (en) Compounds and methods for the treatment of cancer
PL381863A1 (pl) Zastosowanie związków pirydyniowych i sposób leczenia
GB0602857D0 (en) The treatment of sialorrhoea
GB0705517D0 (en) Therapeutic compounds and their use
PL383157A1 (pl) Sposób otrzymywania monochloropropandioli i dichloropropanoli

Legal Events

Date Code Title Description
REFS Decisions on refusal to grant patents (taken after the publication of the particulars of the applications)